{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:28:14Z","timestamp":1791444494224,"version":"4.3.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Pharmaceutical Company Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s40261-016-0455-2","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T22:08:53Z","timestamp":1472854133000},"page":"39-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetic Drug\u2013Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men"],"prefix":"10.1007","volume":"37","author":[{"given":"Yuuichi","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Shiino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayako","family":"Horii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukikuni","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"issue":"6","key":"455_CR1","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MJT.0000000000000123","volume":"22","author":"BH McCarberg","year":"2015","unstructured":"McCarberg BH, Cryer B. Evolving therapeutic strategies to improve nonsteroidal anti-inflammatory drug safety. Am J Ther. 2015;22(6):e167\u201378.","journal-title":"Am J Ther."},{"key":"455_CR2","volume-title":"Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative effectiveness review No. 4","author":"R Chou","year":"2006","unstructured":"Chou R, Helfand M, Peterson K, Dana T, Roberts C. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative effectiveness review No. 4. Rockville: Agency for Healthcare Research and Quality; 2006."},{"key":"455_CR3","volume-title":"Guideline for peptic ulcer treatment [in Japanese]","author":"Japanese Society of Gastroenterology","year":"2009","unstructured":"Japanese Society of Gastroenterology. Guideline for peptic ulcer treatment [in Japanese]. Tokyo: Nankodo K.K; 2009."},{"issue":"3","key":"455_CR4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/ajg.2009.115","volume":"104","author":"FL Lanza","year":"2009","unstructured":"Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of G. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728\u201338.","journal-title":"Am J Gastroenterol."},{"key":"455_CR5","volume-title":"Evidence-based guideline for gastric ulcer treatment [in Japanese]","author":"Research Group for Assessment and Adaptation of Guideline for Gastric Ulcer","year":"2007","unstructured":"Research Group for Assessment and Adaptation of Guideline for Gastric Ulcer. Evidence-based guideline for gastric ulcer treatment [in Japanese]. 2nd ed. Tokyo: Jiho K.K; 2007.","edition":"2"},{"key":"455_CR6","first-page":"CD002296","volume":"4","author":"A Rostom","year":"2002","unstructured":"Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4:CD002296.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"455_CR7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00535-012-0541-z","volume":"47","author":"K Sugano","year":"2012","unstructured":"Sugano K, Kontani T, Katsuo S, Takei Y, Sakaki N, Ashida K, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2012;47(5):540\u201352.","journal-title":"J Gastroenterol."},{"issue":"6","key":"455_CR8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00535-011-0397-7","volume":"46","author":"K Sugano","year":"2011","unstructured":"Sugano K, Matsumoto Y, Itabashi T, Abe S, Sakaki N, Ashida K, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2011;46(6):724\u201335.","journal-title":"J Gastroenterol."},{"issue":"2","key":"455_CR9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240\u201351.","journal-title":"Aliment Pharmacol Ther."},{"key":"455_CR10","doi-asserted-by":"publisher","unstructured":"Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple-therapy for Helicobacter pylori eradication. Gut. 2016. doi: 10.1136\/gutjnl-2015-311304 (ePub ahead of print).","DOI":"10.1136\/gutjnl-2015-311304"},{"key":"455_CR11","unstructured":"Takeda Takecab (vonoprazan tablets) package insert. Available at: http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_2329030F1020_1_04 . Accessed 9 Aug 2016."},{"issue":"1","key":"455_CR12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231\u20138.","journal-title":"J Pharmacol Exp Ther."},{"issue":"2","key":"455_CR13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.111.185314","volume":"339","author":"JM Shin","year":"2011","unstructured":"Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412\u201320.","journal-title":"J Pharmacol Exp Ther."},{"issue":"5","key":"455_CR14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0192623308320802","volume":"36","author":"AL Berg","year":"2008","unstructured":"Berg AL, Bottcher G, Andersson K, Carlsson E, Lindstrom AK, Huby R, et al. Early stellate cell activation and veno-occlusive-disease (VOD)-like hepatotoxicity in dogs treated with AR-H047108, an imidazopyridine proton pump inhibitor. Toxicol Pathol. 2008;36(5):727\u201337.","journal-title":"Toxicol Pathol."},{"issue":"1","key":"455_CR15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1572-0241.2007.01544.x","volume":"103","author":"J Dent","year":"2008","unstructured":"Dent J, Kahrilas PJ, Hatlebakk J, Vakil N, Denison H, Franzen S, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008;103(1):20\u20136.","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"455_CR16","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2007.08.014","volume":"5","author":"PJ Kahrilas","year":"2007","unstructured":"Kahrilas PJ, Dent J, Lauritsen K, Malfertheiner P, Denison H, Franzen S, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5(12):1385\u201391.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"455_CR17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636\u201348.","journal-title":"Aliment Pharmacol Ther."},{"key":"455_CR18","doi-asserted-by":"publisher","unstructured":"Yamasaki H, Kawaguchi N, Nonaka M, Takahashi J, Morohashi A, Hirabayashi H et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2016. doi: 10.1080\/00498254.2016.1203505 (ePub ahead of print).","DOI":"10.1080\/00498254.2016.1203505"},{"issue":"2","key":"455_CR19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1006\/abio.1994.1180","volume":"218","author":"Y Ozaki","year":"1994","unstructured":"Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem. 1994;218(2):284\u201394.","journal-title":"Anal Biochem."},{"key":"455_CR20","unstructured":"English translation of Attachment 1 of Pharmaceutical and Food Safety Bureau\/Evaluation and Licensing Division Notification No. 1124004. [Guideline for Bioequivalence Studies of Generic Products]. 2016. http:\/\/www.nihs.go.jp\/drug\/be-guide(e)\/be2006e.pdf . Accessed 25 Aug 2016."},{"key":"455_CR21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/DHPS.S71976","volume":"7","author":"JL Goldstein","year":"2015","unstructured":"Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015;7:31\u201341.","journal-title":"Drug Healthc Patient Saf."},{"key":"455_CR22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-230X-13-54","volume":"13","author":"K Sugano","year":"2013","unstructured":"Sugano K, Kinoshita Y, Miwa H, Takeuchi T, Esomeprazole NPSG. Safety and efficacy of long-term esomeprazole 20\u00a0mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. BMC Gastroenterol. 2013;13:54.","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"455_CR23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF02395209","volume":"27","author":"MS Roberts","year":"1984","unstructured":"Roberts MS, McLeod LJ, Cossum PA, Vial JH. Inhibition of platelet function by a controlled release acetylsalicylic acid formulation\u2013single and chronic dosing studies. Eur J Clin Pharmacol. 1984;27(1):67\u201374.","journal-title":"Eur J Clin Pharmacol."},{"issue":"6","key":"455_CR24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF00637504","volume":"23","author":"LM Ross-Lee","year":"1982","unstructured":"Ross-Lee LM, Elms MJ, Cham BE, Bochner F, Bunce IH, Eadie MJ. Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function. Eur J Clin Pharmacol. 1982;23(6):545\u201351.","journal-title":"Eur J Clin Pharmacol."},{"issue":"5","key":"455_CR25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","volume":"41","author":"B Meibohm","year":"2002","unstructured":"Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41(5):329\u201342.","journal-title":"Clin Pharmacokinet."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0455-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0455-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T21:55:39Z","timestamp":1498341339000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0455-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0455-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]}}}